ELYSIS reached an important milestone in 2024, granting its first technology licence to Rio Tinto for the construction of a demonstration plant that will be equipped with 10 ELYSIS(TM) pots operating ...

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) fell 2.4% in pre-open trading Friday as the company announced a strategic reorganization focusing on key valu ...

ELYSIS is pleased to announce the appointment of François Perras as President and Chief Executive Officer, effective, 2025.